Thera-SAbDab

ENVAFOLIMAB

>   Structural Summary
TherapeuticEnvafolimab
TargetPDL1
Heavy ChainQVQLVESGGGLVQPGGSLRLSCAASGKMSSRRCMAWFRQAPGKERERVAKLLTTSGSTYLADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAADSFEDPTCTLVTSS
Light Chainna
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatSingle Domain Variable Fragment;H
IsotypeG1
Highest Clinical Trial (October '21)Preregistration
Estimated Status (October '21)Active
Recorded Developmental Technologyna
INN Year Proposed2018
INN Year Recommended2019
Companies InvolvedAlphamab, 3D Medicines, Sun Yat-Sen University
Conditions Approvedna
Conditions ActiveBiliary cancer, Breast cancer, Solid tumours, Gastric cancer, Gastrointestinal cancer, Hepatitis B, Malignant fibrous histiocytoma, Soft tissue sarcoma
Conditions Discontinuedna
Notes

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy